NCT02643303 - A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 28, 2016

Primary Completion Date

February 23, 2022

Study Completion Date

February 23, 2022

Conditions

Head and Neck Squamous Cell CarcinomaBreast CancerSarcomaMerkel Cell CarcinomaCutaneous T-Cell LymphomaMelanomaRenal CancerBladder CancerProstate CancerTesticular CancerSolid Tumor

Interventions

DRUG

Durvalumab

DRUG

Tremelimumab

DRUG

Poly-ICLC

Trial Locations (7)

10029

Research Facility, New York

14263

Research Facility, Buffalo

22908

Research Facility, Charlottesville

30322

Research Facility, Atlanta

43614

Research Facility, Toledo

44195

Research Facility, Cleveland

03756

Research Facility, Lebanon